Skip to content
OpenCapital
Get started

Rapid Micro Biosystems RPID Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss

Other financials

Income statement

See full
Revenue$8.0M+11.1%
Gross profit$371.0K-8.2%
Operating income-$13.9M-18.8%
Net income-$14.3M-26.7%
EPS (diluted)-$0.31-19.2%

Balance sheet

See full
Cash & equivalents$14.1M-26.8%
Total debt$23.8M+301%
Total equity$20.4M-68.9%
Total assets$62.4M-27.0%

Cash flow

See full
Operating cash flow-$15.1M-66.1%
CapEx$394.0K+23.5%
Free cash flow-$15.5M-64.7%

Valuation

See full
Market cap$86.19M-43.8%
Enterprise value$95.86M-31.7%
P/S2.5×-2.6×

Profitability

See full
Operating margin-144.2%-12.7pp
Net margin-145.8%-5.0pp
FCF margin-110.5%-14.9pp

Returns & leverage

See full
Return on equity-116.7%-620pp
Debt / equity1.2×+1.1×
Current ratio2.6×-2.0×

Where this comes from

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's debt securities, available-for-sale, amortized cost, after allowance for credit loss.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapid Micro Biosystems's debt securities, available-for-sale, amortized cost, after allowance for credit loss?
Rapid Micro Biosystems (RPID) reported debt securities, available-for-sale, amortized cost, after allowance for credit loss of $9.14M in Q1 2026.
How has Rapid Micro Biosystems's debt securities, available-for-sale, amortized cost, after allowance for credit loss changed year-over-year?
Rapid Micro Biosystems's debt securities, available-for-sale, amortized cost, after allowance for credit loss decreased by 59.8% year-over-year, from $22.75M to $9.14M.